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Abstract
Kru ¨ppel-like factor 8 (KLF8) has only recently been identified to be involved in tumor cell proliferation and invasion of
several different tumor entities like renal cell carcinoma, hepatocellular carcinoma and breast cancer. In the present study,
we show for the first time the expression of KLF8 in gliomas of different WHO grades and its functional impact on glioma
cell proliferation. In order to get information about KLF8-mRNA regulation qPCR was performed and did not reveal any
significant difference in samples (n=10 each) of non-neoplastic brain (NNB), low-grade gliomas (LGG, WHOuII) and
glioblastomas (GBM, WHOuIV). Immunohistochemistry of tissue samples (n=7 LGG, 11 AA and 12 GBM) did not show any
significant difference in the fraction of KLF8-immunopositive cells of all analyzed cells in LGG (87%), AA (80%) or GBM (89%).
Tissue samples from cerebral breast cancer metastasis, meningiomas but also non-neoplastic brain demonstrated
comparable relative cell counts as well. Moreover, there was no correlation between KLF8 expression and the expression
pattern of the assumed proliferation marker Ki67, which showed high variability between different tumor grade (9% (LGG),
6% (AA) and 15% (GBM) of Ki67-immunopositive cells). Densitometric analysis of Western blotting revealed that the relative
amount of KLF8-protein did also not differ between the highly aggressive and proliferative GBM (1.05) compared to LGG
(0.93; p,0.05, students t-test). As demonstrated for some other non-glial cancer entities, KLF8-knockdown by shRNA in U87-
MG cells confirmed its functional relevance, leading to an almost complete loss of tumor cell proliferation. Selective
blocking of KLF8 might represent a novel anti-proliferative treatment strategy for malignant gliomas. Yet, its simultaneous
expression in non-proliferating tissues could hamper this approach.
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Introduction
The zinc finger-containing transcription factor Kru ¨ppel-like
factor 8 (KLF8) [1] has first been accounted to act as a
downstream molecule for integrin-dependent FAK-signaling in
mouse fibroblast NIH3T3 cells [2]. Zhao and colleagues reported
that stimulation of the focal adhesion kinase (FAK) led to a FAK/
Src/PI-3K triggered KLF8 binding to cyclin D1 and consecutive
entrance into the replication phase of the cell cycle in these cells.
In different solid cancers outside the central nervous system (CNS),
FAK has been implicated as a leading signal transduction
molecule for crucial integrin-dependent steps of adhesion and
proliferation as well as invasion and migration of tumor cells [3,4].
These attributes would render KLF8 also a very interesting
target for novel treatment approaches in GBM. Unlike the
inhibitory effect achieved by blocking of upstream molecules as for
example integrin avb3, a more downstream interference might be
less susceptible against compensatory ‘‘back-up’’ mechanisms of
malignant tumor cells. Moreover, recent findings support the
importance of KLF8 in malignant cell transformation and tumor
growth of several different non-CNS tumors [5,6,7,8]. KLF8
protein and mRNA expression was not only significantly higher in
renal cell carcinoma (RCC) than in non-neoplastic renal tissue,
inhibition of KLF8 via siRNA could also induce cell apoptosis in
vitro and reduced tumor growth in vivo [7]. Furthermore, KLF8
overexpression was demonstrated in highly metastatic or recurrent
hepatocellular carcinomas (HCC). In this study, KLF8 could even
be linked with clinical data and revealed to be a significant
predictor for overall and progression-free survival [8]. Only
recently additional data was presented, which identified KLF8 as
an activator for matrix metalloproteinase 9 (MMP9), leading to
enhanced tumor invasion of human breast cancer [9].
This study was performed in order to assess for the first time
expression and functional impact of KLF8, a member of the
Kru ¨ppel-like transcription factor family, in primary brain tumors.
Extended knowledge of proliferation related transcription factors
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development of new therapeutic drugs in the complex and
demanding treatment strategies of glial brain tumors.
Methods
Patients and tissue samples
Tissue samples were obtained from patients with newly
diagnosed gliomas. Clinical data of these patients are summarized
in supplementary Table S1. Histological diagnosis was performed
on paraffin embedded sections according to the World Health
Organization (WHO) criteria [10]. Histologically confirmed low-
grade astrocytomas (LGG; WHOuII, n=10), anaplastic astrocy-
tomas (AA, WHOuIII, n=11) and glioblastomas (GBM;
WHOuIV, n=12), as well as non-neoplastic brain tissue (NNB,
n=10) obtained from patients with epileptic focus resection were
included in this study. Additionally, meningioma, cerebral breast
cancer metastasis and renal cell carcinoma (n=3 each) were
analyzed. Written informed consent was obtained from all patients
according to the study approval of the ethics committee of the
Ludwig-Maximilians-Universita ¨t Mu ¨nchen. Tumor tissue samples
were either paraffin embedded for immunohistochemistry or snap
frozen and homogenized for PCR and Western blot analysis.
PCR
RNA from snap frozen tumor samples (n=10 NNB, LGG and
GBM) or U87-MG cells (5610
5) was isolated with the RNeasyH
Mini-Kit (QIAGEN GmbH) according to manufacturers ` instruc-
tions. The RNA (a total of 0.2 mg for each sample) was then
reverse transcribed using the QuantiTectH Reverse Transcription
Kit (QIAGEN GmbH). The semi-quantitative PCR was per-
formed using the LightCycler system (Roche Diagnostics GmbH)
according to manufacturers instructions by using QuantiFast
SYBRH Green PCR Kit (QIAGEN GmbH). In brief, 2 ml cDNA
was used for amplification in a total volume of 20 ml per capillary.
The following primer pair was used: KLF8 fwd: 59TGG AAC
CAG TGG ACC TCT CC39; KLF8 rev: 59-ATC TGC TGG
CTA CCA GTG CT-39. The fluorescent signals obtained were
used to calculate the relative amount of template DNA. Signals for
KLF8 were normalized against the TBP housekeeping gene (for
U87-MG) and HPRT1 and RRN18S housekeeping genes (for
tissue) (QuantiTectH Primer Assays, QIAGEN).
Histology and Immunohistochemistry
The histological diagnosis was made by the members of the
local histopathological conference according to the 2007 WHO
classification of tumors of the central nervous system. For
histopathological examination, samples were fixed with 4%
buffered formalin (Fisher Scientific GmbH) and embedded in
paraffin. Tumor morphology in 2 mm paraffin sections was
visualized using hematoxylin and eosin staining. For immunohis-
tochemistry, sections were subjected to standardized staining on a
benchmark staining machine with a 3,39-diaminobenzidine (DAB)
detection system according to the manufacturers instructions
(Ventana Medical Systems). Primary antibodies against the
transcription molecule KLF8 (1:100, AV31533, Sigma) were used
for detection of human KLF8. Proliferation activity in the
respective areas was determined using anti-human Ki67 antibody
(mouse monoclonal, clone MIB-1, Dako). For quantification of
KLF8 and Ki67, first a representative area was selected in the
KLF8 stained section and the corresponding area was identified in
consecutive Ki67-stained section. Then, for all cases representative
pictures (4006 magnification, area: 35525 mm
2 for each area) of
the selected regions in the KLF8 and Ki67 sections were taken
with a BX50 Olympus microscope. Cell count was performed
using Cell D Software according to the manufacturers instructions.
All immunohistochemical staining procedures and antibody
concentrations were adjusted to avoid overstaining (saturation),
understaining (beyond detection limit) or non-specific background
artifacts as described elsewhere [11]. Negative controls were
performed by omitting the primary antibody, tissue samples from
a renal parenchyma served as a positive control (Figure S1 A).
For immunocytochemistry, malignant glioma cell line U87-MG
was cultured in vitronectin-coated (2%) CultureSlides (BD Falcon
GmbH) and fixed with 4% paraformaldehyde (20uC, 15 min). For
detection of nuclear proteins, permeabilization with methanol
(220uC, 20 sec) was performed. After incubation with primary
antibody against KLF8 (1:100, H00011279-B01, Abnova GmbH)
diluted in antibody diluent, slides were treated with biotinylated
secondary antibody (1:750, BA-2000, Vector Laboratories, Inc.)
for 15 min followed by alkaline phosphatase conjugated strepta-
vidin (1:1000, SA-5100, Vector Laboratories, Inc.) for 30 min.
Visualization was performed using 5-bromo-4-chloro-3-indoyl
phosphate p-toluidine salt and p-nitro blue tetrazolium chloride
solution (BCIP/NBT, Vector Laboratories, Inc.), followed by
counterstaining with eosine (Sigma-Aldrich Chemie GmbH).
Slides were dehydrated by an ascending ethanol sequence (70%,
96%, 100%) and histol (Carl Roth GmbH und Co. KG) and
finally covered (Figure S1 B). Negative controls were performed by
omitting the primary antibody.
Western Blot
Western blotting was performed from tissue samples of NNB,
LGG and GBM (n=10 each) as described previously with only
slight modifications [11]. Snap frozen tissue sections were minced
and homogenized on ice under addition of NP-40 lysis buffer
(10 mM Tris/HCl, 150 mM NaCl, 10% Glycerol, 0.5% Nonidet
P-40 (Roche Diagnostics GmbH), 2 mM EDTA pH 8.0 (Sigma-
Aldrich Chemie GmbH) containing 1 mmol/l DTT, 0,5 mmol/l
PMSF (Sigma-Aldrich Chemie GmbH), PIC (Sigma-Aldrich
Chemie GmbH), Phosphatase Inhibitor Cocktail 1 and 2
(Sigma-Aldrich Chemie GmbH)). After incubation in lysis buffer
for 15 min on ice, lysates were centrifuged at 14000 x g, 4uC for
10 min. The quantification of protein in the supernatant was
performed via Bradford protein assay (BioRad Laboratories
GmbH). Briefly, equal amounts of protein (30 mg) were separated
by SDS-Page (10%) followed by transfer to PVDF membrane
(BioRad Laboratories GmbH). After Blocking with 1 x Roti-Block
(Carl Roth GmbH & Co. KG) for 2 hrs, the membrane was
incubated with primary antibody (1:1000, SAB2101277, Sigma-
Aldrich Chemie GmbH) diluted in 1 x Roti-Block at 4uC over
night. The membrane was washed in TBS-Tween 20 (Sigma-
Aldrich Chemie GmbH) for three times, incubated with secondary
antibody (1:10000, 170-5046, BioRad Laboratories GmbH) and
again washed for three times. Proteins were visualized by
enhanced chemiluminiscence detection system (Pierce ECL
Western Blotting Substrate, Thermo Fisher Scientific Germany
Ltd. & Co. KG). Equal loading was confirmed by use of a mouse
anti-b-actin antibody (1:1000, sc-47778, Santa Cruz Biotechnol-
ogy, Inc.).
Semiquantitative analysis of Western blot results was performed
by densitometric measurements with the software ImageJ (Image
Processing and Analysis in Java) by using a protein ladder
(Invitrogen GmbH) for calibration of the molecular weights.
Optical Density was normalized onto the house keeping gene b-
actin, equalling 1.0. To compare different membranes, equal
aliquots of a protein lysate of U87-MG cells were processed on
each membrane.
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The human glioblastoma cell line U87-MG was cultured in
Dulbecco’s modified Eagle medium (DMEM, Biochrom AG)
containing minimum essential medium (MEM) with non-essential
amino acids (NEAA, Invitrogen GmbH), fetal bovine serum (FBS,
10%, Biochrom AG) and additives (penicillin-streptomycin-
glutamine, Invitrogen GmbH). Cells were cultured on vitronec-
tin-coated (2%; Sigma-Aldrich GmbH) plastic flasks unto subcon-
fluency for all purposes (TPP AG).
KLF8-knockdown via shRNA transfection
Assay ready U87-MG KLF8-knockdown as well as scrambled
shRNA transfected cells were purchased from Sirion Biotech,
Martinsried, Germany. Therefore, U87-MG cells from our
laboratory stock were transfected with adenoviral vectors by Q-
tech silencing technique as described elsewhere [12]. Shortly,
double stranded sh-oligonucleotide cassettes were cloned under
the control of human U6-promoter into plasmid A. The U6-
shDNA portion was then transferred by recombination into the
backbone of a standard E1/E3 deleted, replication-deficient Ad5
vector which was contained in plasmid B. Subsequent virus rescue
and production was carried out in HEK293 cells. Virus
purification was performed chromatographically using commer-
cially available adenovirus purification kits. Infectious virus titers
were determined with Adeno-XTM Rapid Titer Kit (Clontech
Figure 1. Quantitative PCR. Samples of low-grade gliomas LGG and
GBM (n=10 each) were analyzed for KLF8-mRNA regulation. Compared
to non-neoplastic brain (set as 100%), qPCR did not show any
significant difference in the amount of KLF8-mRNA in LGG (97.1%)
and GBM (99.3%).
doi:10.1371/journal.pone.0030429.g001
Figure 2. Immunohistochemistry for KLF8 and Ki67 in gliomas of different WHO-grades. Immunohistochemistry for KLF8 demonstrates
that gliomas of different WHO-grades (A: uII, D: uIII, G: uIV) show expression of the transcription factor. The expression is ubiquitous in the tissue and
shows no grade dependency. Higher magnification demonstrates that KLF8 immunopositive staining is mainly visible in the nuclei but also present in
the cytoplasm (Figure 3). Proliferation marker Ki67 is strongly expressed in nuclei of a small population of cells in the same tumors (B: uII, E: uIII, H: uIV).
Routine HE staining was performed on paraffin embedded sections of all tumor tissue samples (C: uII, F: uIII, I: uIV). Scale bars as indicated. For cell
count analysis of KLF8 and Ki67 see Table S2.
doi:10.1371/journal.pone.0030429.g002
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medium (c.f. cell culture) was used.
For verification of KLF8-knockdown, cells were monitored over
a period of 72 hrs after cell seeding. Maximum level of KLF8-
knockdown within the test period was found to be .90% 72 hrs
after seeding as quantified by qPCR. Remaining protein
expression after successful knockdown of KLF8-mRNA was
analyzed by Western Blot of the nuclear protein fraction in all
transfected cells. Therefore, cells were washed twice with 1 x PBS
and first lysed to remove cytoplasma proteins with buffer A
[10 mM HEPES pH 7.9; 10 mM KCl; 1.5 mM MgCl2 x6H 2O;
2 mM DTT; 10 mg/ml Aprotinin; 0.5 mM PMSF] for 10 min on
ice followed by treatment with ultrasound in a Bandelin Sonorex
Super RK 52 H device (HFfrequency 35 kHz, HFpower 60/
120 W) for 5 sec, short incubation on ice and again treatment with
ultrasound for 3 sec. After centrifugation at 14000 x g, 4uC for
10 sec, equal amount of 60% Glycerol was added to the
supernatant. For extraction of nuclear fraction, same volume of
buffer B [20 mM HEPES pH 7.9; 25% Glycerol; 0.42 M NaCl;
1.5 mM MgCl2 x6H 2O; 0.2 mM EDTH pH 8,0; 2 mM DTT;
10 mg/ml Aprotinin; 0,5 mM PMSF] was added to the pellet
followed by incubation on ice for 45 min. After centrifugation for
10 min at 8000 x g, 4uC the same volume of buffer C [20 mM
HEPES pH 7,9; 20% Glycerol; 0,1 mM KCl; 0,05 mM EDTH
pH 8,0; 2 ml/ml Igepal] was added.
Proliferation Assay
To confirm functional relevance of KLF8-knockdown in the
transfected U87-MG cells, a proliferation assay was performed.
Scrambled shRNA-transfected U87-MG cells as well as KLF8-
knockdown U87-MG cells were seeded at passage 1 after
transfection in equal amounts (each 1.0610
4 cells/cm
2)i n
vitronectin coated 24-well plates and cultured in DMEM medium
for as long as 4 days after seeding. Each day, cell counts were
measured by direct cell counting of vital cells via trypan blue
staining (Sigma-Aldrich Chemie GmbH). Total cell counts were
documented for each well. After four repetitions with equal
experimental conditions, cell counts were compared and mean
values as well as standard deviations were calculated.
Statistical Analysis
Further statistical analysis of the data was performed with R
(www.r-project.org). Since the experimental design included
repeated measurements for two experimental groups (KLF8-
knockdown, scarmbled shRNA-transfected) at different time points
(days 1, 2, 3, 4), a two-way ANOVA (library ‘‘stats’’, function
Figure 3. KLF8 and Ki67 expression in non-CNS tumors. KLF8 (A, C, E) and Ki67 (B, D, F) protein expression was analyzed in some additional
tissue samples of breast cancer metastasis (A, B), meningioma (C, D) and non-neoplastic brain (E, F). All tissue samples analyzed confirmed ubiquitous
expression of this transcription molecule, irrespective of the assumed proliferation rate.
doi:10.1371/journal.pone.0030429.g003
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(experimental group, time point) on the number of the cells
simultaneously. Both parameters, experimental group and time
point, as well as their interaction were identified as significant.
Therefore, the 8 groups of replicate samples (2 experimental
groups x 4 time points) were tested pairwise with t-Tests. ‘‘Holm’’
correction was applied to correct for multiple testing. (library
‘‘stats’’, function ‘‘pairwise.t.test’’).
Results
KLF8-mRNA is expressed in glioma tissue of different
grades as well as non-neoplastic brain
Compared to non-neoplastic brain, qPCR revealed no signif-
icant difference in KLF8-mRNA expression in lysates of low-grade
gliomas (97.1%, relative expression) as well as glioblastomas
(99.3%) (Figure 1).
Expression of KLF8 is prominent in tumor cells of high-
and low grade gliomas but does not correlate with Ki67
expression
Immunohistochemical staining for KLF8 demonstrated abun-
dant protein expression in glial tumors of different WHO grades
(Figure 2). Relative cell counts of KLF8-immunopositive cells were
obtained as percentage of the total number of cells within the same
areas as displayed in supplementary Table S2. There was no
significant difference in calculated relative cell counts of KLF8-
positive cells in LGG (86%), AA (80%) and GBM (89%).
Even if KLF8 is a putative proliferation marker in other non-
glial tumor entities, not all KLF8 immunopositive glioma cells did
also stain positive for Ki67, which is a widely used proliferation
marker in glial tumors. However, Ki67 protein expression itself
only weakly correlated with tumor grading as revealed by relative
cell counts of adjacent sections from the same tumor areas
(Figure 2). The median Ki67 index was 9% (range: 0–39%) in the
LGG, 6% (0–12%) in the AA and 16% (1–46%) in the highly
proliferative GBM (Table S2).
Independent expression of Ki67 and KLF8 was also demon-
strated in other tissues. Samples from breast cancer metastasis,
meningioma and non-neoplastic brain showed ubiquitous expres-
sion of KLF8, irrespective of the assumed proliferation rate
(Figure 3). Renal parenchyma served as a positive control for
KLF8 expression (Figure S1 A).
Quantitative analysis reveals comparable relative KLF8
protein expression in gliomas of different WHO grades
Densitometric analysis of Western blot experiments revealed an
overall density of KLF8 (36.89 kDa) of 1.7260.85 in GBM
compared to 1.5261.16 in LGG thus indicating that KLF8
protein is expressed without significant difference (Figure 4).
Hence, Western Blot quantification confirms similar relative KLF8
protein expression also in non-neoplastic brain (1.6360.54).
KLF8-knockdown terminates proliferation in U87-MG
Since KLF8 has been demonstrated to be essential in
proliferation of non-glial tumors, we selectively inhibited KLF8
by shRNA transfection in U87-MG glioma cell line (detected
positive for KLF8, Figure S1 B). This led to an almost complete
knockdown of KLF8-mRNA expression as quantified by qPCR
(Figure 5 A) and reduced KLF8 protein expression as demon-
strated by Western Blot analysis (Figure 5 B) in U87-MG.
Proliferation assay of U87-MG transfected with KLF8 shRNA
or scrambled shRNA revealed significant inhibition over a period
of 3 days after seeding as outlined in figure 6 (Figure 6).
In order to investigate the significance of this observation, two-
way ANOVA was used which analyzes the influence of the two
parameters (experimental group, time point). Both parameters
(experimental group, time point) as well as their interaction (p-
Values: 3.2e-13, 1.0e-10, 3.5e-12) were identified as significant.
Therefore, the groups were further tested pairwise with t-Tests
followed by a correction for multiple testing. The scrambled
shRNA-transfected cells showed proliferation with significantly
increasing cell numbers from day to day (p-Values: 0.042, 1.6e-04,
5.8e-08). In contrast, there was no statistically significant difference
at a p-Value # 0.05 between the cell numbers for KLF8 shRNA
transfected cells measured on days 1, 2, 3 and 4 (p-Values: 1, 1,
0.8) which indicates no proliferation in KLF8 shRNA-knockdown
cells during the whole period analyzed.
Discussion
Kru ¨ppel-like factor 8 (KLF8) has been demonstrated to mediate
cell cycle progression downstream of focal adhesion kinase (FAK)
by upregulating cyclin D1. Enhanced expression of KLF8 has
been shown in several types of non-CNS tumor cells and primary
tumor tissues [6] where it has been associated with malignancy.
Although this might implicate similarities in glial tumors, detailed
knowledge about morphological KLF8 expression in gliomas is still
lacking.
Our immunohistochemical and Western blot studies demon-
strate for the first time that KLF8, a pivotal transcription factor for
Figure 4. Western blot and densitometric analysis of KLF8
Western blots in gliomas. Western blot was performed for samples
from gliomas of different WHO grades (GBM uIV, LGG uII) as well as non-
neoplastic brain (NNB) (A). Densitometric analysis of the Western blot
revealed no significant difference in expression of the transcription
factor KLF8 in GBM compared to LGG and non-neoplastic brain samples.
Protein expression was normalized to the house-keeping gene b-actin
(set as 1.0, B).
doi:10.1371/journal.pone.0030429.g004
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grades (Figure 2). However, no significant difference was seen
between glioma dignities both on protein level (immunohisto-
chemistry, Western blot analysis) or mRNA level (PCR). Even if
KLF8 has been depicted an ubiquitous factor [1], this is surprising
since other highly proliferative non-CNS tumors such as recurrent
Figure 5. PCR and WB of KLF8 after shRNA knockdown in U87-MG. (A) U87-MG cells transfected with either scrambled (scr) or KLF8-shRNA
(kd) were cultivated for up to 3 days (day 0=day of seeding). Cells were harvested every 24 hrs and RNA was isolated, transcribed into cDNA and
amplified by qPCR; data were normalized relative to levels of the house keeping gene TBP. Semi-quantitative qPCR displayed a clear knock-down in
KLF8 expression already 48 hrs after transfection (day 0). Expression levels decreased to about 10% in KLF8-shRNA treated cells compared to cells
treated with scrambled shRNA on day 2 after seeding. (B) Subsequent Western Blot analysis of the nuclear fraction of KLF8-kd U87-MG cells on day 4
after seeding revealed that KLF8 protein was still detectable in all transfected U87-MG cells but only to a small extent in the KLF8-knockdown cells
indicating that shRNA-knockdown was successful in these transfected cells in concordance with the qPCR results (Figure 5A).
doi:10.1371/journal.pone.0030429.g005
Figure 6. Proliferation of U87-MG in KLF8 shRNA knockdown as well as scrambled shRNA control cells. U87-MG cells were transfected
with KLF8-shRNA or the scramble control, as indicated. Proliferation rate was high in the scrambled control cells during the whole time course after
seeding. In contrast, KLF8-knockdown cells did show only minimal proliferation at day 2 after seeding but ceased further proliferation from day 3 on.
Asterisk indicates significant difference (Mann-Whitney U test; p,0.05).
doi:10.1371/journal.pone.0030429.g006
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significant overexpression of this signaling molecule [8]. On the
other hand, these highly aggressive non-CNS tumors have
mesenchymal cell origin and KLF8 has also been shown to
trigger epithelial-to-mesenchymal transition [13], which might in
part explain overexpression of KLF8 in these tumors.
Since KLF8 has been linked to proliferative activity of non-CNS
tumors, we additionally stained consecutive sections with the
widely used proliferative marker Ki67 [14]. While KLF8 was
expressed in almost all glial tumors, only a limited fraction of the
tumor cells were found to be immunopositive for the Ki67. Despite
a tendency towards a grade dependent expression between GBM
and LGG, this was not supported by the AA which had an even
lower proliferative index than the LGG in our series (Table S2).
Moreover, tumor-grade dependent groups were heterogeneous
with regard to Ki67 expression. This inconsistent correlation with
the histological malignancy has already been found by other
groups, [15,16], even if Ki67 is often used to quantify the
proliferative potential of gliomas in the clinical setting [14,17].
Thus, our results show no correlation of Ki67 with KLF8
expression and as described earlier, Ki67 should therefore be
interpreted with caution in the evaluation of proliferative activity
of glial tumors of all WHO grades.
Even if functional relevance of markers like Ki67 or KLF8 does
not necessarily depend on protein or mRNA upregulation,
deficient expression might still have an impact on cell prolifera-
tion. Hence, we subjected U87-MG cells to shRNA-knockdown of
KLF8, which led to a significant time dependent impairment in
their proliferation, providing first evidence for the potency of this
transcription factor in human gliomas. This is in line with previous
reports where inhibition of endogenous KLF8 by siRNA reduced
cell cycle progression in NIH3T3 mouse fibroblasts [2]. By
targeting the downstream transcription molecule KLF8, we tried
to exclude compensatory pathways which might counteract
treatment effects on an upstream level. Yet, there is still a
multitude of KLF8-related posttranscriptional regulations as
described lately in non-malignant tissues [18,19,20]; e.g. modu-
lation of KLF8 transcriptional activity by co-activator proteins or
by modification via acetylation [13]. It now has to be elucidated
whether KLF8 regulation follows similar mechanisms in glioma
models in order to identify possible new key molecules.
Conclusion
In summary, we have identified Kru ¨ppel-like factor 8 expression
in the tumor parenchyma of human gliomas of different WHO
grades without quantitative correlation to tumor grade or Ki67
expression. Inhibition of this potent transcription factor led to an
almost complete loss of glioma cell proliferation in vitro, but its
ubiquitous expression might counteract KLF8-targeting in malig-
nant gliomas as a future antiproliferative strategy. Nevertheless,
this work significantly advances our knowledge on glioma specific
KLF8 expression patterns but independent functional relevance.
This study also provides information that will be useful in the
future in order to study or target KLF8-activated gene-specific
cellular functions in brain tumors.
Supporting Information
Table S1 Relevant clinical data from patients with
gliomas of different WHO grades. Histologically confirmed
low-grade astrocytomas (LGG; WHOuII), anaplastic astrocytomas
(AA, WHOuIII) and glioblastomas (GBM; WHOuIV) from both
genders (male/female) were included in our study. Tumor tissue was
subjected to the different analysis as indicated: IHC = immunohis-
tochemistry,WB = Westernblot,PCR = polymerase chainreaction.
(TIF)
Table S2 Cell count analysis of KLF8 and Ki67 in
gliomas of different WHO grades. In order to obtain more
objective data on KLF8 expression, cell counts of KLF8-
immunopositive tumor cells were calculated in relation to the
total number of cells within the tumor areas. There was no
statistically significant difference in cell counts of KLF8-positive
tumor cells of LGG (87%), AA (80%) and GBM (89%).
(TIF)
Figure S1 Positive controls for KLF8 immunohisto-/
immunocytochemistry. (A) Due to their known high expres-
sion of KLF8 and in accordance with the manufacturers guide,
tissue samples from a renal parenchyma served as a positive
control for immunohistochemical procedures and calibration of
overall staining intensity. Scale bar as indicated. (B) Untreated
U87-MG were subjected to immunocytochemical staining for
KLF8, which was displayed mainly in the nucleus of the cells as
visualized by BCIP/NBT. Scale bar as indicated.
(TIF)
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